[{"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-001", "question": "A 58-year-old man with metastatic castration-resistant prostate cancer (mCRPC) on enzalutamide develops progressive disease with new liver metastases. He is switched to docetaxel plus prednisone. After 6 cycles, his PSA declines by 80% and liver lesions shrink, but he develops new-onset bilateral gynecomastia, mild hyperpigmentation of palmar creases, and worsening fatigue. Serum studies show: testosterone 12 ng/dL (low), LH 0.1 mIU/mL (low), FSH 0.2 mIU/mL (low), cortisol 4 mcg/dL (8 AM, low), ACTH 15 pg/mL (inappropriately normal), TSH 0.8 mIU/L, free T4 1.0 ng/dL. What is the most likely underlying mechanism for his new symptoms?", "options": ["Secondary adrenal insufficiency due to docetaxel-induced autoimmune hypophysitis", "Ectopic ACTH secretion from prostate cancer cells transforming to small cell neuroendocrine carcinoma", "Inhibition of CYP17A1 by residual enzalutamide leading to combined glucocorticoid and mineralocorticoid deficiency", "Docetaxel-induced primary testicular failure with subsequent feedback suppression of gonadotropins", "Paraneoplastic production of beta-hCG by treatment-emergent neuroendocrine-differentiated prostate cancer"], "answer": "C", "answer_index": 2, "explanation": "The clinical picture suggests combined glucocorticoid and androgen deficiency with low ACTH, consistent with secondary adrenal insufficiency due to central suppression. Enzalutamide is a potent androgen receptor inhibitor but also inhibits multiple CYP enzymes, including CYP17A1, which is required for glucocorticoid and androgen synthesis. When docetaxel suppresses tumor burden, residual enzalutamide (with a long half-life) continues to block adrenal steroidogenesis, causing a late-presenting adrenal crisis. Ectopic ACTH would elevate ACTH; autoimmune hypophysitis typically elevates TSH and causes other pituitary deficiencies; primary testicular failure elevates LH/FSH; beta-hCG causes gynecomastia but not adrenal insufficiency.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: N (No answer defensible). Verdict: No option correctly explains the patient’s secondary adrenal insufficiency; the keyed answer C is factually incorrect. Key stem clues: low morning cortisol with inappropriately normal ACTH, low testosterone and gonadotropins, new gynecomastia and palmar hyperpigmentation, recent docetaxel + prednisone, prior enzalutamide. The pattern indicates secondary adrenal insufficiency from chronic glucocorticoid exposure, but none of the choices describe this. Option A invokes docetaxel-induced autoimmune hypophysitis, which is unsupported and would also cause central hypothyroidism (TSH is normal). Option B (ectopic ACTH) would raise ACTH and cortisol. Option C claims enzalutamide inhibits CYP17A1, which is false; enzalutamide does not block adrenal steroidogenesis. Option D describes primary testicular failure, which would raise LH/FSH. Option E (β‑hCG) does not explain adrenal insufficiency. Thus, no answer is defensible. Medical accuracy issues: enzalutamide does not inhibit CYP17A1; hyperpigmentation is inconsistent with low ACTH; autoimmune hypophysitis does not elevate TSH. Minimal fix: Replace option C with 'Secondary adrenal insufficiency from chronic prednisone suppressing the HPA axis' and set that as the key.\",\n\"medical_accuracy_score\":   \t\"2\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"N\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (No answer defensible). Verdict: No option correctly explains the patient’s secondary adrenal insufficiency; the keyed answer C is factually incorrect. Key stem clues: low morning cortisol with inappropriately normal ACTH, low testosterone and gonadotropins, new gynecomastia and palmar hyperpigmentation, recent docetaxel + prednisone, prior enzalutamide. The pattern indicates secondary adrenal insufficiency from chronic glucocorticoid exposure, but none of the choices describe this. Option A invokes docetaxel-induced autoimmune hypophysitis, which is unsupported and would also cause central hypothyroidism (TSH is normal). Option B (ectopic ACTH) would raise ACTH and cortisol. Option C claims enzalutamide inhibits CYP17A1, which is false; enzalutamide does not block adrenal steroidogenesis. Option D describes primary testicular failure, which would raise LH/FSH. Option E (β‑hCG) does not explain adrenal insufficiency. Thus, no answer is defensible. Medical accuracy issues: enzalutamide does not inhibit CYP17A1; hyperpigmentation is inconsistent with low ACTH; autoimmune hypophysitis does not elevate TSH. Minimal fix: Replace option C with 'Secondary adrenal insufficiency from chronic prednisone suppressing the HPA axis' and set that as the key.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-002", "question": "A 32-year-old woman with common variable immunodeficiency (CVID) on monthly IVIG develops acute severe headache, photophobia, and neck stiffness 36 hours after her infusion. LP shows: opening pressure 28 cm H2O, WBC 2/μL, protein 40 mg/dL, glucose 60 mg/dL (serum 95 mg/dL). Gram stain and culture negative. MRI brain with contrast is normal. She has had two similar but milder episodes in the past 12 months, always within 48 hours of IVIG. Which intervention is most likely to prevent recurrence while maintaining adequate immune protection?", "options": ["Switch to subcutaneous immunoglobulin (SCIG) at the same monthly dose", "Pre‑infusion high‑dose corticosteroid (e.g., methylprednisolone 1 g IV)", "Change IVIG product to a sucrose‑free, low‑osmolality formulation", "Administer IVIG at a slower infusion rate (e.g., over 72 hours) with pre‑hydration", "Replace IVIG with prophylactic antibiotics and as‑needed plasma infusions"], "answer": "A", "answer_index": 0, "explanation": "This describes aseptic meningitis secondary to IVIG, a well‑known complication related to high peak IgG levels and cytokine release. Switching to SCIG provides steady‑state IgG levels without peaks, dramatically reducing meningitis risk while maintaining protection. Slower infusion or changing formulation may reduce but not eliminate risk in susceptible patients. Pre‑infusion steroids are not routinely effective and pose long‑term risks. Discontinuing immunoglobulin replacement in CVID would lead to serious infections despite antibiotics.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy / Immunology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. Key stem clues: Recurrent acute headache, photophobia, neck stiffness consistently 36-48h post-IVIG; CSF shows elevated opening pressure but normal WBC/protein/glucose; negative cultures; normal MRI; underlying CVID requiring replacement. This pattern is classic for IVIG-induced aseptic meningitis. Option A (switch to SCIG) is uniquely defensible: SCIG provides steady-state IgG without peaks implicated in cytokine-mediated reactions, maintaining immune protection. Alternatives are clearly inferior: B (high-dose steroids) lacks evidence and adds long-term toxicity; C (sucrose-free formulation) addresses excipient-related renal toxicity, not meningitis; D (72h infusion) is impractical and unlikely to prevent peak-mediated effects; E (antibiotics/plasma) is non-standard and inadequate for CVID. No logical flaws: single best answer is unambiguous, key matches, no contradictions. Medical accuracy is excellent: aligns with current literature and practice guidelines supporting SCIG for severe IVIG adverse reactions. CSF profile is atypical but reported in IVIG-meningitis. Minimal fix: None required; item is board-ready.\",\"medical_accuracy_score\":   \"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. Key stem clues: Recurrent acute headache, photophobia, neck stiffness consistently 36-48h post-IVIG; CSF shows elevated opening pressure but normal WBC/protein/glucose; negative cultures; normal MRI; underlying CVID requiring replacement. This pattern is classic for IVIG-induced aseptic meningitis. Option A (switch to SCIG) is uniquely defensible: SCIG provides steady-state IgG without peaks implicated in cytokine-mediated reactions, maintaining immune protection. Alternatives are clearly inferior: B (high-dose steroids) lacks evidence and adds long-term toxicity; C (sucrose-free formulation) addresses excipient-related renal toxicity, not meningitis; D (72h infusion) is impractical and unlikely to prevent peak-mediated effects; E (antibiotics/plasma) is non-standard and inadequate for CVID. No logical flaws: single best answer is unambiguous, key matches, no contradictions. Medical accuracy is excellent: aligns with current literature and practice guidelines supporting SCIG for severe IVIG adverse reactions. CSF profile is atypical but reported in IVIG-meningitis. Minimal fix: None required; item is board-ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-003", "question": "An 87‑year‑old man with moderate Alzheimer dementia (MoCA 14/30), hypertension, and chronic kidney disease (eGFR 28 mL/min/1.73m²) is admitted from assisted living for acute confusion and agitation. He has been on donepezil 10 mg daily for 3 years. In the ED, he receives lorazepam 1 mg IM for severe agitation, with minimal effect. Inpatient medications include amlodipine, losartan, and aspirin. Over 48 hours, he develops persistent non‑rhythmic myoclonic jerks of the face and limbs, fluctuating alertness, and autonomic instability (HR 110-140, BP 170/95). EEG shows generalized periodic discharges with triphasic morphology. MRI brain is unchanged from baseline (moderate atrophy). What is the most likely diagnosis?", "options": ["Creutzfeldt‑Jakob disease", "Serotonin syndrome from an undetected SSRI", "Donepezil toxicity in the setting of acute kidney injury", "Nonconvulsive status epilepticus due to underlying neurodegeneration", "Acute anticholinergic delirium from a newly started medication"], "answer": "C", "answer_index": 2, "explanation": "The presentation with myoclonus, autonomic instability, altered mental status, and triphasic waves on EEG in a patient on donepezil with advanced CKD suggests donepezil toxicity. Donepezil is renally excreted, and acute kidney injury (even mild) can precipitate toxicity. Triphasic waves are classically associated with metabolic/toxic encephalopathies, including acetylcholinesterase inhibitor toxicity. Creutzfeldt‑Jakob disease would show rapid progression and MRI diffusion abnormalities. Serotonin syndrome requires a serotonergic agent. Nonconvulsive status typically shows rhythmic epileptiform discharges. Anticholinergic delirium causes dry skin, not myoclonus or triphasic waves.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. The stem provides a unique solution: an 87-year-old with severe CKD (eGFR 28) on donepezil develops myoclonus, autonomic instability, and triphasic waves. Donepezil is renally excreted; accumulation in renal failure produces cholinergic toxicity with these features. Triphasic waves are characteristic of toxic/metabolic encephalopathy. Alternatives are appropriately excluded: CJD would show MRI diffusion restriction; no serotonergic agent is present for serotonin syndrome; NCSE exhibits rhythmic epileptiform discharges, not triphasic waves; anticholinergic delirium is mechanistically opposite. No internal contradictions exist. Medical accuracy is high: the association between donepezil, renal failure, and this clinical picture is well-documented, though the rationale's reference to 'acute kidney injury' is not explicitly stated—severe CKD alone is sufficient. Minor nuance: guidelines recommend dose reduction in eGFR <30, but toxicity at 10 mg remains plausible. Minimal fix: Specify 'acute on chronic kidney injury' to clarify the precipitating factor.\",\"medical_accuracy_score\":   \"4\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. The stem provides a unique solution: an 87-year-old with severe CKD (eGFR 28) on donepezil develops myoclonus, autonomic instability, and triphasic waves. Donepezil is renally excreted; accumulation in renal failure produces cholinergic toxicity with these features. Triphasic waves are characteristic of toxic/metabolic encephalopathy. Alternatives are appropriately excluded: CJD would show MRI diffusion restriction; no serotonergic agent is present for serotonin syndrome; NCSE exhibits rhythmic epileptiform discharges, not triphasic waves; anticholinergic delirium is mechanistically opposite. No internal contradictions exist. Medical accuracy is high: the association between donepezil, renal failure, and this clinical picture is well-documented, though the rationale's reference to 'acute kidney injury' is not explicitly stated—severe CKD alone is sufficient. Minor nuance: guidelines recommend dose reduction in eGFR <30, but toxicity at 10 mg remains plausible. Minimal fix: Specify 'acute on chronic kidney injury' to clarify the precipitating factor.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-004", "question": "A 45‑year‑old woman with metastatic HER2‑positive breast cancer (bone, liver) on first‑line therapy with trastuzumab, pertuzumab, and docetaxel achieves a partial response after 6 cycles. Maintenance trastuzumab/pertuzumab is continued. One year later, surveillance CT shows a new 2 cm pancreatic tail mass, biopsy‑proven adenocarcinoma consistent with breast primary (ER‑/PR‑/HER2 3+ by IHC). Next‑generation sequencing of the pancreatic lesion reveals an activating mutation in PIK3CA (H1047R) and no HER2 amplification by NGS (though IHC remains 3+). She has never received a CDK4/6 inhibitor or everolimus. What is the most appropriate next systemic therapy?", "options": ["Continue trastuzumab/pertuzumab and add capecitabine", "Switch to trastuzumab deruxtecan (T‑DXd)", "Switch to lapatinib plus capecitabine", "Switch to everolimus plus exemestane", "Switch to alpelisib plus fulvestrant"], "answer": "B", "answer_index": 1, "explanation": "This represents HER2‑positive breast cancer with apparent HER2 discordance (IHC 3+ but no amplification by NGS) and acquired PIK3CA mutation. Trastuzumab deruxtecan (T‑DXd) is effective even in HER2‑low disease and has shown activity in HER2‑positive cancers resistant to trastuzumab/pertuzumab. Continuing dual HER2 blockade with chemotherapy is less likely to work given possible HER2‑negative clone emergence. Lapatinib/capecitabine is an older second‑line option but inferior to T‑DXd. Everolimus/exemestane or alpelisib/fulvestrant target hormone pathway/PIK3CA but are for HR‑positive disease; here the tumor is ER‑/PR‑.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V (valid). Verdict: The keyed answer B (trastuzumab deruxtecan) is the correct best choice. Key stem clues: metastatic HER2‑positive breast cancer with prior progression on trastuzumab/pertuzumab; new pancreatic metastasis with HER2 IHC 3+ but no NGS amplification; PIK3CA H1047R mutation; ER/PR negativity. These findings indicate HER2‑directed therapy resistance while retaining HER2 protein expression, making T‑DXd the preferred next‑line agent, as it retains activity in HER2‑low and HER2‑positive refractory disease. Alternative options are inferior: continuing dual HER2 blockade (A) is unlikely to overcome resistance; lapatinib/capecitabine (C) is outdated and less effective; everolimus/exemestane (D) and alpelisib/fulvestrant (E) are indicated only for HR‑positive disease. No internal contradictions or missing critical details; the stem supports a single best answer. Medical accuracy: The scenario reflects current practice, and the explanation aligns with FDA approvals and NCCN guidelines. Minor nuance: NGS for HER2 amplification is non‑standard, but this does not affect the best‑answer selection. No logical or medical errors. Minimal fix: None required.\",\n\"medical_accuracy_score\":   \t\"4\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (valid). Verdict: The keyed answer B (trastuzumab deruxtecan) is the correct best choice. Key stem clues: metastatic HER2‑positive breast cancer with prior progression on trastuzumab/pertuzumab; new pancreatic metastasis with HER2 IHC 3+ but no NGS amplification; PIK3CA H1047R mutation; ER/PR negativity. These findings indicate HER2‑directed therapy resistance while retaining HER2 protein expression, making T‑DXd the preferred next‑line agent, as it retains activity in HER2‑low and HER2‑positive refractory disease. Alternative options are inferior: continuing dual HER2 blockade (A) is unlikely to overcome resistance; lapatinib/capecitabine (C) is outdated and less effective; everolimus/exemestane (D) and alpelisib/fulvestrant (E) are indicated only for HR‑positive disease. No internal contradictions or missing critical details; the stem supports a single best answer. Medical accuracy: The scenario reflects current practice, and the explanation aligns with FDA approvals and NCCN guidelines. Minor nuance: NGS for HER2 amplification is non‑standard, but this does not affect the best‑answer selection. No logical or medical errors. Minimal fix: None required.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-005", "question": "A 28‑year‑old woman with idiopathic anaphylaxis presents with recurrent episodes of urticaria, angioedema, wheezing, and hypotension occurring 2-3 times monthly despite high‑dose antihistamines and montelukast. She undergoes exhaustive evaluation: normal tryptase, negative specific IgE to foods/venoms/drugs, no mastocytosis on bone marrow biopsy, and no physical urticaria triggers. During a supervised oral challenge to placebo in clinic, she develops identical symptoms with hypotension. Serum collected during the event shows elevated prostaglandin D2 (PGD2) but normal histamine and tryptase. Which therapy is most likely to be effective in preventing future episodes?", "options": ["Omalizumab (anti‑IgE)", "Rituximab (anti‑CD20)", "Imatinib (tyrosine kinase inhibitor)", "Continuous intravenous epinephrine infusion", "NSAID (e.g., indomethacin) prior to suspected triggers"], "answer": "E", "answer_index": 4, "explanation": "Elevated PGD2 with normal histamine/tryptase during symptoms suggests a prostaglandin‑mediated disorder, possibly a mast cell activation syndrome variant or idiopathic flush‑related anaphylaxis. NSAIDs inhibit cyclooxygenase and reduce PGD2 production, which can prevent episodes in select patients with prostaglandin‑driven symptoms. Omalizumab targets IgE‑mediated pathways, not primarily prostaglandin‑mediated. Rituximab is for autoimmune conditions. Imatinib is for mastocytosis with KIT mutations. Continuous epinephrine is not a preventive therapy and carries high risk.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy / Immunology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V. Verdict: Correct best answer. Key stem clues: idiopathic anaphylaxis with negative specific IgE, normal baseline and episode tryptase, and elevated serum PGD2 during a placebo-triggered attack, pointing to a prostaglandin-driven mast cell activation syndrome rather than classic IgE- or clonal mast cell disease. The answer options include only one therapy that directly inhibits prostaglandin synthesis (NSAID COX blockade). Omalizumab targets IgE-dependent pathways, Rituximab and Imatinib address unrelated mechanisms, and continuous epinephrine is an acute rescue measure, leaving NSAID as the only plausible preventive agent. No internal contradictions exist, and the stem provides sufficient data to select a single best option. Medical accuracy issue: Routine NSAID prophylaxis for anaphylaxis is not standard practice; NSAIDs can precipitate bronchospasm, gastrointestinal bleeding, and anaphylaxis in susceptible individuals, and evidence for efficacy in PGD2-mediated disease is limited to small case series. The item omits safer, guideline-supported alternatives such as cromolyn sodium. Minimal fix: Replace the NSAID option with 'Cromolyn sodium (mast cell stabilizer)' or add a clarifying sentence that the patient has no NSAID contraindications and has tolerated prior NSAID exposure, thereby justifying its selection as the most targeted therapy among the choices.\",\n\"medical_accuracy_score\":   \t\t\t\t\t\t\t\"3\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. Key stem clues: idiopathic anaphylaxis with negative specific IgE, normal baseline and episode tryptase, and elevated serum PGD2 during a placebo-triggered attack, pointing to a prostaglandin-driven mast cell activation syndrome rather than classic IgE- or clonal mast cell disease. The answer options include only one therapy that directly inhibits prostaglandin synthesis (NSAID COX blockade). Omalizumab targets IgE-dependent pathways, Rituximab and Imatinib address unrelated mechanisms, and continuous epinephrine is an acute rescue measure, leaving NSAID as the only plausible preventive agent. No internal contradictions exist, and the stem provides sufficient data to select a single best option. Medical accuracy issue: Routine NSAID prophylaxis for anaphylaxis is not standard practice; NSAIDs can precipitate bronchospasm, gastrointestinal bleeding, and anaphylaxis in susceptible individuals, and evidence for efficacy in PGD2-mediated disease is limited to small case series. The item omits safer, guideline-supported alternatives such as cromolyn sodium. Minimal fix: Replace the NSAID option with 'Cromolyn sodium (mast cell stabilizer)' or add a clarifying sentence that the patient has no NSAID contraindications and has tolerated prior NSAID exposure, thereby justifying its selection as the most targeted therapy among the choices.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-006", "question": "An 82‑year‑old woman with aortic stenosis (mean gradient 38 mm Hg, AVA 0.9 cm²), COPD (FEV1 45%), and stage 3 CKD is admitted with syncope. She lives independently but reports declining energy over 6 months. She is evaluated by cardiology and deemed high risk for surgical AVR but a candidate for TAVR. During shared decision‑making, which factor, if present, would most strongly argue against proceeding with TAVR?", "options": ["Recent fall with subdural hematoma requiring reversal of apixaban 3 months ago", "Moderate‑severe mitral regurgitation due to annular dilation", "Life expectancy estimated at less than 12 months due to metastatic lung cancer diagnosed 2 months ago", "Frailty score consistent with slow gait and low grip strength but able to perform ADLs", "Asymptomatic 4 cm abdominal aortic aneurysm noted on pre‑TAVR CT"], "answer": "C", "answer_index": 2, "explanation": "TAVR is indicated to improve quality of life and survival in patients with severe symptomatic aortic stenosis whose life expectancy is >12 months. A life expectancy <12 months due to metastatic cancer makes the procedural risks and recovery burdens unjustifiable. Recent subdural hematoma is a relative contraindication but may be timed. Moderate‑severe MR often improves post‑TAVR. Frailty alone does not preclude TAVR if the patient can participate in rehabilitation. A 4 cm AAA is below threshold for repair and not a contraindication.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. The stem's key discriminating clue is that TAVR benefit requires life expectancy >12 months to justify procedural risks and recovery burden. Option C (metastatic lung cancer, <12 months) directly violates this core selection criterion, making it the most compelling contraindication. Comparative analysis of alternatives confirms uniqueness: A (subdural hematoma 3 months ago) is a relative, time-sensitive bleeding risk that can be managed; B (moderate-severe MR) often improves post-TAVR due to afterload reduction; D (frailty with intact ADLs) is a modifiable risk factor rather than absolute barrier; E (4 cm AAA) is below intervention threshold and clinically irrelevant. No logical flaws: the 'most strongly argues against' comparative framing yields a single best answer without ambiguity or need for unstated assumptions. Medical accuracy is gold-standard: aligns with ACC/AHA/ESC TAVR guidelines emphasizing anticipated survival >1 year. Minor nuance: AVA 0.9 cm² is borderline severe, but combined with mean gradient 38 mmHg and classic symptoms, the scenario remains clinically valid. Minimal fix: None required.\",\"medical_accuracy_score\":   \t\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. The stem's key discriminating clue is that TAVR benefit requires life expectancy >12 months to justify procedural risks and recovery burden. Option C (metastatic lung cancer, <12 months) directly violates this core selection criterion, making it the most compelling contraindication. Comparative analysis of alternatives confirms uniqueness: A (subdural hematoma 3 months ago) is a relative, time-sensitive bleeding risk that can be managed; B (moderate-severe MR) often improves post-TAVR due to afterload reduction; D (frailty with intact ADLs) is a modifiable risk factor rather than absolute barrier; E (4 cm AAA) is below intervention threshold and clinically irrelevant. No logical flaws: the 'most strongly argues against' comparative framing yields a single best answer without ambiguity or need for unstated assumptions. Medical accuracy is gold-standard: aligns with ACC/AHA/ESC TAVR guidelines emphasizing anticipated survival >1 year. Minor nuance: AVA 0.9 cm² is borderline severe, but combined with mean gradient 38 mmHg and classic symptoms, the scenario remains clinically valid. Minimal fix: None required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]